Bloomberg reported on Nov. 13 that AstraZeneca cut about 600 roles across its U.S. respiratory and immunology commercial teams. Some affected staff were reportedly involved in marketing the asthma medicines Breztri and Airsupra. Some employees may be reassigned to other roles; the number who will leave the company is unclear. The cuts are part of a three-year plan targeting about $1.5 billion in annual savings, with the savings intended to support investment in AstraZeneca’s drug pipeline. The plan may involve up to $2 billion in one-time restructuring costs. AstraZeneca declined to comment on the reported job cuts. The company has said the broader restructuring is not expected to reduce its overall workforce. Sources: AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In AstraZeneca cuts 600 sales jobs in US, Bloomberg News ... AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports AstraZeneca Cuts US Commercial Workforce as Part of USD 1.5 Billion Annua...
- Get link
- X
- Other Apps